Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T42932
|
|||||
| Target Name |
Toll-like receptor 1 (TLR1)
|
|||||
| Synonyms |
Toll/interleukin-1 receptor-like protein; TIL; KIAA0012; CD281
Click to Show/Hide
|
|||||
| Gene Name |
TLR1
|
|||||
| Target Type |
Patented-recorded target
|
[1] | ||||
| Function |
Specifically recognizes diacylated and triacylated lipopeptides. Cooperates with TLR2 to mediate the innate immune response to bacterial lipoproteins or lipopeptides. Forms the activation cluster TLR2:TLR1:CD14 in response to triacylated lipopeptides, this cluster triggers signaling from the cell surface and subsequently is targeted to the Golgi in a lipid-raft dependent pathway. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Participates in the innate immune response to microbial agents.
Click to Show/Hide
|
|||||
| BioChemical Class |
Toll-like receptor
|
|||||
| UniProt ID | ||||||
| Sequence |
MTSIFHFAIIFMLILQIRIQLSEESEFLVDRSKNGLIHVPKDLSQKTTILNISQNYISEL
WTSDILSLSKLRILIISHNRIQYLDISVFKFNQELEYLDLSHNKLVKISCHPTVNLKHLD LSFNAFDALPICKEFGNMSQLKFLGLSTTHLEKSSVLPIAHLNISKVLLVLGETYGEKED PEGLQDFNTESLHIVFPTNKEFHFILDVSVKTVANLELSNIKCVLEDNKCSYFLSILAKL QTNPKLSNLTLNNIETTWNSFIRILQLVWHTTVWYFSISNVKLQGQLDFRDFDYSGTSLK ALSIHQVVSDVFGFPQSYIYEIFSNMNIKNFTVSGTRMVHMLCPSKISPFLHLDFSNNLL TDTVFENCGHLTELETLILQMNQLKELSKIAEMTTQMKSLQQLDISQNSVSYDEKKGDCS WTKSLLSLNMSSNILTDTIFRCLPPRIKVLDLHSNKIKSIPKQVVKLEALQELNVAFNSL TDLPGCGSFSSLSVLIIDHNSVSHPSADFFQSCQKMRSIKAGDNPFQCTCELGEFVKNID QVSSEVLEGWPDSYKCDYPESYRGTLLKDFHMSELSCNITLLIVTIVATMLVLAVTVTSL CSYLDLPWYLRMVCQWTQTRRRARNIPLEELQRNLQFHAFISYSGHDSFWVKNELLPNLE KEGMQICLHERNFVPGKSIVENIITCIEKSYKSIFVLSPNFVQSEWCHYELYFAHHNLFH EGSNSLILILLEPIPQYSIPSSYHKLKSLMARRTYLEWPKEKSKRGLFWANLRAAINIKL TEQAKK Click to Show/Hide
|
|||||
| 3D Structure | Click to Show 3D Structure of This Target | AlphaFold | ||||
| Cell-based Target Expression Variations | Top | |||||
|---|---|---|---|---|---|---|
| Cell-based Target Expression Variations | ||||||
| Drug Binding Sites of Target | Top | |||||
|---|---|---|---|---|---|---|
| Ligand Name: (2r)-3-{[(2s)-3-Hydroxy-2-(Palmitoylamino)propyl]thio}propane-1,2-Diyl Dihexadecanoate | Ligand Info | |||||
| Structure Description | Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide | PDB:2Z7X | ||||
| Method | X-ray diffraction | Resolution | 2.10 Å | Mutation | No | [2] |
| PDB Sequence |
SEFLVDRSKN
34 GLIHVPKDLS44 QKTTILNISQ54 NYISELWTSD64 ILSLSKLRIL74 IISHNRIQYL 84 DISVFKFNQE94 LEYLDLSHNK104 LVKISCHPTV114 NLKHLDLSFN124 AFDALPICKE 134 FGNMSQLKFL144 GLSTTHLEKS154 SVLPIAHLNI164 SKVLLVLGET174 YGEKEDPEGL 184 QDFNTESLHI194 VFPTNKEFHF204 ILDVSVKTVA214 NLELSNIKCV224 LEDNKCSYFL 234 SILAKLQTNP244 KLSNLTLNNI254 ETTWNSFIRI264 LQLVWHTTVW274 YFSISNVKLQ 284 GQLDFRDFDY294 SGTSLKALSI304 HQVVSDVFGF314 PQSYIYEIFS324 NMNIKNFTVS 334 GTRMVHMLCP344 SKISPFLHLD354 FSNNLLTDTV364 FENCGHLTEL374 ETLILQMNQL 384 KELSKIAEMT394 TQMKSLQQLD404 ISQNSVSYDE414 KKGDCSWTKS424 LLSLNMSSNI 434 LTDTIFRCLP444 PRIKVLDLHS454 NKIKSIPKQV464 VKLEALQELN474 VASNQLKSVP 484 DGIFDRLTSL494 QKIWLHTNPW504 DCSCPRIDYL514 SRWLNKNSQK524 EQGSAKCSGS 534 GKPVRSIICP544
|
|||||
|
|
||||||
| Click to View More Binding Site Information of This Target with Different Ligands | ||||||
| Different Human System Profiles of Target | Top |
|---|---|
|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Pathway Affiliation
of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function.
Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes
(Pharmacol Rev, 58: 259-279, 2006).
Biological Network Descriptors
of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database.
The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information
(Front Pharmacol, 9, 1245, 2018;
Curr Opin Struct Biol. 44:134-142, 2017).
Human Similarity Proteins
Human Pathway Affiliation
Biological Network Descriptors
|
|
| KEGG Pathway | Pathway ID | Affiliated Target | Pathway Map |
|---|---|---|---|
| Toll-like receptor signaling pathway | hsa04620 | Affiliated Target |
|
| Class: Organismal Systems => Immune system | Pathway Hierarchy | ||
| Degree | 9 | Degree centrality | 9.67E-04 | Betweenness centrality | 8.42E-08 |
|---|---|---|---|---|---|
| Closeness centrality | 2.01E-01 | Radiality | 1.35E+01 | Clustering coefficient | 7.78E-01 |
| Neighborhood connectivity | 2.01E+01 | Topological coefficient | 2.79E-01 | Eccentricity | 12 |
| Download | Click to Download the Full PPI Network of This Target | ||||
| Target Affiliated Biological Pathways | Top | |||||
|---|---|---|---|---|---|---|
| KEGG Pathway | [+] 2 KEGG Pathways | + | ||||
| 1 | Toll-like receptor signaling pathway | |||||
| 2 | Tuberculosis | |||||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Toll-Like Receptor Pathways in Autoimmune Diseases. Clin Rev Allergy Immunol. 2016 Feb;50(1):1-17. | |||||
| REF 2 | Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell. 2007 Sep 21;130(6):1071-82. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.